Literature DB >> 1834122

Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma.

M J Trotter1, D J Chaplin, P L Olive.   

Abstract

Effects of the vasoconstrictor angiotensin II on tumour microvascular perfusion and oxygenation were examined in the murine SCCVII carcinoma grown subcutaneously in C3H/He mice. Angiotensin II infusion (2 micrograms/kg/min) caused an increase in mouse arterial blood pressure from 85 (2) mm Hg (mean, S.D.) to 112 (7) mm Hg. During drug infusion, tumour red blood cell (RBC) flow (measured by laser doppler flowmetry) increased 206 (50%) (P less than 0.001) in unanaesthetised animals and 305 (90%) (P less than 0.001) in mice immobilised with ketamine and diazepam. As assessed using a fluorescent double-staining technique, angiotensin II reduced staining mismatch (indicative of intermittent blood flow) in SCCVII microvasculature from 8.1 (2.5%) of total vessels to 2.0 (1.3%) (P less than 0.001). However, a large proportion of this reduction could be attributed to volume loading. Angiotensin II reduced but did not completely eliminate the radiobiological acute hypoxia which results from intermittent tumour vessel non-perfusion. We propose that angiotensin II improves tumour microcirculatory flow distribution via its systemic actions, by elevating perfusion pressure, thereby preventing collapse and/or temporary flow stasis in tumour microvessels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834122     DOI: 10.1016/0277-5379(91)90140-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

Review 1.  Mild temperature hyperthermia and radiation therapy: role of tumour vascular thermotolerance and relevant physiological factors.

Authors:  Robert J Griffin; Ruud P M Dings; Azemat Jamshidi-Parsian; Chang W Song
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

2.  Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review.

Authors:  Bryan T Oronsky; Susan J Knox; Jan J Scicinski
Journal:  Transl Oncol       Date:  2012-04-01       Impact factor: 4.243

Review 3.  Drug delivery and transport to solid tumors.

Authors:  Seong Hoon Jang; M Guillaume Wientjes; Dan Lu; Jessie L S Au
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

4.  Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging.

Authors:  H Sato; K Sugiyama; M Hoshi; M Urushiyama; K Ishizuka
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

Review 5.  Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response.

Authors:  Mark W Dewhirst; Yiting Cao; Benjamin Moeller
Journal:  Nat Rev Cancer       Date:  2008-06       Impact factor: 60.716

6.  Modification of tumour blood flow using the hypertensive agent, angiotensin II.

Authors:  G M Tozer; K M Shaffi
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

7.  Disparate responses of tumour vessels to angiotensin II: tumour volume-dependent effects on perfusion and oxygenation.

Authors:  O Thews; D K Kelleher; P Vaupel
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

Review 8.  NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.

Authors:  Jan Scicinski; Bryan Oronsky; Shoucheng Ning; Susan Knox; Donna Peehl; Michelle M Kim; Peter Langecker; Gary Fanger
Journal:  Redox Biol       Date:  2015-07-02       Impact factor: 11.799

9.  The response of tumour vasculature to angiotensin II revealed by its systemic and local administration to 'tissue-isolated' tumours.

Authors:  G M Tozer; K M Shaffi
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

10.  Effects of intravenous infusion of dopamine on tumor blood flow in rat subcutis.

Authors:  S Tanda; K Hori; S Saito; Q H Zhang; H C Li; M Suzuki
Journal:  Jpn J Cancer Res       Date:  1994-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.